Skip to content

Clinical study on the effect of transcranial time-interference stimulation with different frequency differences on the symptom improvement of patients with depression

The study on the clinical symptom improvement and brain mechanism of patients with refractory depression through transcranial time interference stimulation with different frequency differences

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112516
Enrollment
Unknown
Registered
2025-11-15
Start date
2025-11-15
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, anxiety, insomnia, loss of pleasure, etc

Interventions

40Hz frequency difference tTIS true stimulation group:(Group with frequency difference of 40 Hz + tTIS): The two applied frequencies are 2000 Hz and 2040 Hz, with a stimulation duration of 30 minutes
The TIS pseudo-stimulation group:(Group with sham tTIS): A frequency difference of either 40 Hz or 130 Hz was applied to half of the participants each, with a duration of 1 minute (30 seconds ramp-up,
130Hz frequency difference tTIS true stimulation group:(Group with frequency difference of 130 Hz + tTIS): The two applied frequencies are 2000 Hz and 2130 Hz, with a stimulation duration of 30 minute

Sponsors

Affiliated Kangning Hospital of Ningbo University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years, right-handed; 2. Meeting the diagnostic criteria for depression in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5); 3.Total score of Hamilton Depression Rating Scale-24 (HAMD-24) >=20; 4.According to the Mozley Staging Method (MSM), it is classified as moderate to severe treatment-resistant, with a score higher than 6; 5.Normal results in physical examination, medical history, vital signs, routine blood/urine/stool tests, liver and kidney function, electrolytes, electrocardiogram (ECG), electroencephalogram (EEG), and other indicators; 6.Willing to actively cooperate with treatment after fully understanding the safety of transcranial temporal interference stimulation (tTIS), and signing the informed consent form along with their family members. 7.Both have taken selective serotonin reuptake inhibitor SSRI) drugs and have been on a stable dose of antidepressants for at least 2 weeks without effect

Exclusion criteria

Exclusion criteria: 1.Has a history of severe physical illness and depression caused by psychoactive substances and non-substance-dependent substances; 2.Patients who have metal or electronic devices implanted in their bodies, such as intracranial metal foreign bodies, cochlear implants, cardiac pacemakers, and metal stents, etc. 3.There is a risk of epilepsy seizure. The patient has a history of brain disorders, head trauma, alcohol abuse, abnormal electroencephalogram, MRI evidence of brain structure abnormalities, or a family history of epilepsy. 4.Those with psychotic symptoms who require combined use of antipsychotic drugs; 5.Individuals who have received other physical therapies such as ECT, TMS, or tES, as well as systematic psychological therapy, within the two months prior to enrollment.

Design outcomes

Primary

MeasureTime frame
Scales (including: 1. Hamilton Depression Rating Scale (HAMD-24); 2. Hamilton Anxiety Rating Scale (HAMA); 3. Montgomery-?sberg Depression Rating Scale (MADRS); 4. Pittsburgh Sleep Quality Index (PSQI); 5. Snaith-Hamilton Pleasure Scale (SHAPS); 6. Beck Scale for Suicide Ideation, Chinese Version (BSI-CV); 7. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS); 8. Behavioral Inhibition/Activation Systems Scale (BIS/BAS); 9. Temporal Experience of Pleasure Scale (TEPS); 10.;

Secondary

MeasureTime frame
Electrophysiological indicators (including MRI, EEG, near-infrared spectroscopy, and other neurophysiological measures).;

Countries

China

Contacts

Public ContactDongsheng Zhou

Affiliated Kangning Hospital of Ningbo University

wyzhouds@sina.com+86 574 26302565

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026